Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN321 in Low- or Intermediate-1-Risk MDS
NCT01497145Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- Dec 2011
- Primary completion
- Feb 2014
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 2
01
Overview
A Phase 2 trial of darbepoetin alfa in myelodysplastic syndrome (MDS), sponsored by Kyowa Kirin. Started Dec 2011; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01497145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497145.